Sorrento’s lead programs with short-term milestones consist of two clinical stage immuno-oncology therapies (CD38 CAR-T and CEA CAR-T), and two pain franchise programs (license application review Phase for ZTlido NDA and RTX Phase Ib single epidural injection for cancer pain).

Sorrento is also advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, antibody drug conjugates (ADCs), intracellular targeting antibodies and an oncolytic viral vector (Seprevir®).